Salud financiera de hoja de balance de Argent BioPharma

Salud financiera controles de criterios 3/6

MGC Pharmaceuticals tiene unos fondos propios totales de A$-8.0M y una deuda total de A$9.2M, lo que sitúa su ratio deuda/fondos propios en -114.3%. Sus activos y pasivos totales son A$10.0M y A$18.0M respectivamente.

Información clave

1,366.5%

Ratio deuda-patrimonio

AU$9.18m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$6.48m
Patrimonio	AU$671.75k
Total pasivo	AU$16.66m
Activos totales	AU$17.33m

Actualizaciones recientes sobre salud financiera

Recent updates

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Jun 23

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Mar 09

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Oct 08

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30

Análisis de la situación financiera

Pasivos a corto plazo: MXCLos activos a corto plazo (A$9.4M) no cubren sus pasivos a corto plazo (A$12.4M).

Pasivo a largo plazo: MXCLos activos a corto plazo (A$9.4M) superan a sus pasivos a largo plazo (A$4.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de MXC (401.5%) se considera alta.

Reducción de la deuda: MXCha pasado de 0.2% a 1366.5% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MXC tiene suficiente cash runway para 0 meses según el último flujo de caja libre declarado [flujo de caja libre]], pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: MXC se prevé que disponga de suficiente liquidez para 0 meses según las estimaciones de flujo de caja libre, pero desde entonces ha obtenido capital adicional.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Argent BioPharma

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product

Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021

MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM)

Joint Company Secretary has left the company

MGC Pharmaceuticals Limited Revives Increased Initial Supply Agreement for ArtemiC

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

MGC Pharmaceuticals Ltd Signs Master Suppy and Distribution Agreement with Swiss PharmaCan AG for Artemic Rescue

MGC Pharmaceuticals Limited Announces New In-Vitro Cannabinoid Study on Glioblastoma Treatment